Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Healthcare Biotechnology
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference

GlobeNewswire June 1, 2016

Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials

GlobeNewswire April 13, 2016

Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress(TM) 2016

GlobeNewswire March 30, 2016

Assembly Biosciences to Webcast Upcoming Investor Conferences

GlobeNewswire February 19, 2016

Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract

GlobeNewswire January 27, 2016

Assembly Biosciences Expands Senior Leadership Team

GlobeNewswire January 11, 2016

Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors

GlobeNewswire December 21, 2015

Assembly Biosciences to Present at Jefferies Microbiome Summit

GlobeNewswire December 16, 2015

Clinical Study Shows Assembly Biosciences' Oral Gemicel(TM) Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications

GlobeNewswire December 9, 2015

Trading Ahead of Upcoming Developments - Research on Assembly Biosciences, Integrated Electrical Services, Rosetta Stone and Rightside Group

Accesswire November 30, 2015

Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting

GlobeNewswire October 6, 2015

Assembly Biosciences Discusses Mechanism of Action of Its HBV Antiviral Program at 2nd ANRS HBV Cure Workshop

GlobeNewswire May 19, 2015

Assembly Biosciences Announces Pricing of $75 Million Public Offering of Its Common Stock

GlobeNewswire March 19, 2015

Assembly Biosciences Announces Proposed Public Offering of Common Stock

GlobeNewswire March 18, 2015

Assembly Biosciences to Present at 2015 RBC Capital Markets Healthcare Conference

GlobeNewswire February 20, 2015

Assembly Biosciences Announces Senior Management Changes

GlobeNewswire February 17, 2015

Assembly Biosciences to Present at Investor Conferences

GlobeNewswire December 3, 2014

Assembly Biosciences Announces $15.75 Million Registered Direct Offering

GlobeNewswire October 1, 2014

Assembly Biosciences Provides Update on Status of VEN 307

GlobeNewswire July 25, 2014

Ventrus Biosciences Becomes Assembly Biosciences as Stockholders Approve Merger With Assembly Pharmaceuticals, Inc.

GlobeNewswire July 14, 2014